Acute Cystitis (Bladder Infection): Symptoms & Treatment

• Acute cystitis is a sudden bladder infection causing burning urination, urgency, frequency, and lower-belly pressure, usually caused by E. coli from the gut reaching the bladder.
• Diagnosis is usually simple: a urine dipstick or routine test (Rs 150-500) confirms it; a urine culture (Rs 500-1500) is added for recurrent, complicated, or non-responding infections.
• First-line antibiotics are nitrofurantoin, fosfomycin, or co-trimoxazole (where local resistance is low) — not fluoroquinolones like Cifran, which are now reserved due to resistance and side effects.
• ESBL-producing E. coli is found in 30-50% of community urine cultures in India, making a urine culture far more useful here than in Western settings.
• Finish the full antibiotic course even after you feel better, drink plenty of water, and never self-medicate with leftover or chemist-supplied antibiotics.
• See a doctor urgently for fever, chills, back or flank pain, vomiting, blood in urine, or any UTI symptom during pregnancy — these can signal a kidney infection.

Acute cystitis is acute inflammation of the bladder wall. The word "acute" means recent onset (hours to days, not weeks or months), and "cystitis" means the inflammation is in the bladder rather than higher up in the urinary tract. In the vast majority of cases the cause is bacterial: organisms (most commonly E. coli) travel up the urethra, multiply in the urine, stick to the bladder lining, and trigger the inflammation that produces the classic symptoms.

Less common forms of cystitis exist and are managed differently. Interstitial cystitis (painful bladder syndrome) is a chronic, non-infectious condition that mimics a UTI but does not respond to antibiotics. Chemical cystitis can follow irritation from certain drugs, douches, or instrumentation. Radiation cystitis follows pelvic radiotherapy, eosinophilic cystitis is a rare allergic process, and tubercular cystitis can occur as part of genitourinary TB, which still matters in India. This guide focuses on acute bacterial cystitis, which accounts for the great majority of sudden presentations.

Anatomically, the bladder is a hollow muscular organ in the pelvis behind the pubic bone. It collects urine from the kidneys via the ureters and empties it through the urethra. Its inner lining (the urothelium) normally has strong defences against bacteria, including a protective coating, antimicrobial peptides, and the simple mechanical flushing of urine. Infection develops when these defences are overwhelmed.

The female urethra is short (3-4 cm), straight, and opens close to the vagina and anus. This is the main reason women get far more UTIs than men: gut bacteria like E. coli have a short, easy route to the bladder. Anything that increases that bacterial access — sexual activity, certain hygiene practices, hormonal changes — raises UTI risk.

Acute cystitis is distinguished from an upper urinary tract infection (pyelonephritis, a kidney infection) by the absence of fever, flank pain, severe systemic illness, and significant nausea or vomiting. Lower-tract symptoms — burning, frequency, urgency, and suprapubic pain — without those upper-tract features usually mean cystitis. Pyelonephritis is more serious, needs longer treatment, and sometimes requires hospital care.

Asymptomatic bacteriuria is a separate situation: bacteria show up on a urine culture but there are no symptoms. In most non-pregnant adults this does not need treatment, and treating it simply fuels antibiotic resistance without improving health. The key exceptions are pregnancy and certain procedures involving the urinary tract, where treatment is recommended.

The classic symptoms of acute uncomplicated cystitis are burning urination (dysuria), frequency, urgency, and suprapubic discomfort. Dysuria is the burning, stinging, or sharp pain felt while you pee, often worst toward the end of the stream as the inflamed bladder contracts. Frequency means needing to go far more often than usual — sometimes every 30-60 minutes — while passing only small amounts each time. Urgency is the sudden, hard-to-defer need to urinate, which in older women can spill over into urge leakage.

Suprapubic discomfort sits just above the pubic bone in the lower midline of the belly, usually a dull ache, pressure, or cramping that may worsen as the bladder fills. Some women describe a constant feeling of needing to pee or of not emptying fully. Visible blood in the urine occurs in a meaningful share of women with cystitis; it signals more inflammation but does not automatically mean a more dangerous infection. Blood visible only under the microscope (on a urine test) is even more common.

Urine appearance can change. Cloudy urine reflects white blood cells and bacterial debris; foul-smelling urine can occur but is a notoriously unreliable sign on its own. Colour can range from normal pale yellow to cloudy, pink- or rust-tinged (with blood), or dark amber (with dehydration). Visible pus or sediment points to significant infection.

Onset is usually quick. Women often describe waking with mild burning that worsens over hours, or symptoms appearing within a day of a trigger such as sex. The jump from minor discomfort to an obvious UTI can take just 12-24 hours. Many women recognise a familiar "it's starting" feeling from past episodes.

Some features suggest this is NOT simple cystitis and need prompt review: fever above 38°C (100.4°F), chills, flank or back pain (the kidney area), nausea and vomiting, feeling systemically unwell, confusion (especially in older women), or severe pelvic pain beyond ordinary suprapubic ache. These can point to a kidney infection or, rarely, blood-borne infection.

Presentations can also be atypical. Older women may have few symptoms and instead show confusion or a general decline. Women with diabetes may feel less unwell despite significant infection. Pregnant women may have vague symptoms — or asymptomatic bacteriuria that still needs treating. If you are unsure whether your symptoms are a UTI at all, it helps to know how a bladder infection differs from a yeast infection or bacterial vaginosis, and that persistent or unexplained urinary frequency has many possible causes.

In a healthy, non-pregnant woman with classic symptoms, acute uncomplicated cystitis can often be diagnosed clinically without testing — especially if she has had similar episodes that responded to antibiotics. That said, urine testing is cheap and widely available in India and adds useful confirmation. The two main tests are urinalysis (often called urine routine examination, or urine R/E) and urine culture.

Urinalysis combines a dipstick and microscopy. The dipstick strip can detect nitrites (suggesting bacteria, particularly E. coli), leukocyte esterase (indicating white cells from inflammation), blood, protein, glucose, and ketones. Microscopy looks for white cells (pyuria), red cells, and bacteria. In a symptomatic woman, a positive nitrite plus leukocyte esterase strongly supports a UTI; a negative result makes it less likely but does not completely rule it out.

Urinalysis is inexpensive in India: roughly Rs 150-500 at chain labs (SRL, Metropolis, Thyrocare, Dr Lal PathLabs) or hospital OPDs, and free or near-free at government primary health centres. Many gynaecology and general practice clinics run a dipstick in-house with results in minutes. Because it is so simple and accessible, there is rarely a good reason to skip it.

Urine culture is more definitive: it grows the specific organism and tests which antibiotics will kill it. The usual threshold for significance is 100,000 CFU/mL in a clean-catch midstream sample, though lower counts (1,000-10,000 CFU/mL) can matter in a clearly symptomatic woman. Cultures take 24-72 hours, longer for full sensitivities. Culture is particularly valuable for recurrent UTI, complicated UTI, treatment failures, suspected resistant organisms, and pregnancy.

Urine culture costs roughly Rs 500-1500 at Indian chain labs, more for extended sensitivity testing. The report names the organism, the colony count, and a sensitivity pattern showing which drugs work and which do not — information that is genuinely valuable given India's rising rates of resistant E. coli.

Sample collection matters. The standard technique is a clean-catch midstream sample: separate the labia, clean the area, start urinating into the toilet, collect the middle part of the stream in a sterile container, then finish into the toilet. This limits contamination from vaginal or skin flora. If contamination is suspected (mixed growth on culture), the test may need repeating. Catheter samples are reserved for specific situations and are uncommon for routine outpatient diagnosis.

Major guidelines — from the IDSA (Infectious Diseases Society of America), the AUA (American Urological Association), and European bodies — agree on a clear set of first-line antibiotics for acute uncomplicated cystitis: nitrofurantoin, co-trimoxazole (trimethoprim-sulfamethoxazole, where local resistance is acceptable), and fosfomycin. These were chosen because they are active against E. coli, concentrate in urine, have favourable side-effect profiles for short courses, and do relatively little to drive resistance compared with broader-spectrum drugs.

Nitrofurantoin (Niftran in India, also sold as macrocrystals or sustained-release) is one of the most-used cystitis drugs. Standard dosing is 100 mg twice daily for 5 days. It concentrates in urine with little systemic absorption, so it works well for the bladder but not for a kidney infection. It retains excellent activity against E. coli and most other uropathogens. A 5-day generic course typically costs Rs 50-150. Common effects include nausea (take it with food), occasional headache, and rarely brown urine. Avoid it in significant kidney impairment and in late pregnancy.

Co-trimoxazole (TMP-SMX; Bactrim, Septran) is effective where community E. coli resistance is low enough — the guideline threshold is roughly under 20%. In much of India, resistance often exceeds 20-30%, so it is frequently a poor empiric choice, though it remains good when a culture confirms susceptibility. Standard dosing is one double-strength tablet (160/800 mg) twice daily for 3 days, costing around Rs 50-200.

Fosfomycin (Fomicyt) is a single-dose option: 3 g dissolved in water on an empty stomach. The one-and-done convenience improves adherence and it retains activity against many resistant organisms, including some ESBL-producing E. coli. It is generally pricier than nitrofurantoin, around Rs 300-700 per sachet, but the single dose can be worth it.

Other reasonable alternatives in specific situations include pivmecillinam (not widely available in India), nitrofurantoin sustained-release, and culture-guided beta-lactams. Cephalosporins such as cefuroxime axetil and cefixime are sometimes used but drive more collateral resistance than the recommended first-line options.

Fluoroquinolones (ciprofloxacin/Cifran, levofloxacin, ofloxacin) were once routine for cystitis but are now second or third line. They select strongly for resistance across many bacteria; they carry rare but serious risks (tendon rupture, peripheral neuropathy, central nervous system effects, aortic aneurysm); and resistance in Indian E. coli often exceeds 30-50%. The FDA and EMA have warned against using them when alternatives exist. For simple cystitis they are no longer best practice — a point worth remembering if a chemist offers one over the counter.

Extended-spectrum beta-lactamase (ESBL) production is a mechanism by which bacteria — most often E. coli and Klebsiella pneumoniae — become resistant to a wide range of beta-lactam antibiotics, including penicillins and most cephalosporins. ESBL producers are a major problem worldwide and especially in India: recent studies of community urine cultures report ESBL-producing E. coli in 30-50% of samples or more, far above typical Western rates. This shapes how cystitis should be approached here.

The clinical implications are real. Many traditional choices may simply not work against ESBL E. coli, so empiric treatment based on low-resistance settings can fail more often in India. That makes culture-guided treatment more important. Women with risk factors for resistant organisms — recent antibiotic use, recent hospital contact, or recurrent UTI — may need different empiric drugs or earlier, culture-based adjustment.

Antibiotics that keep working against many ESBL E. coli include nitrofurantoin (concentrated in urine and effective for cystitis), fosfomycin (often still active), carbapenems (meropenem, ertapenem — reserved for serious infections, not outpatient cystitis), and amikacin (given by injection for severe infection). Of these, nitrofurantoin and fosfomycin are the practical outpatient options for ESBL cystitis.

Whether to treat empirically or wait for a culture depends on context. For a healthy woman with a first or infrequent episode and no resistance risk factors, empiric nitrofurantoin (or co-trimoxazole if local resistance allows) is reasonable while a culture is pending. For a woman with recurring infections, recent antibiotics, or treatment failures, a culture is essential. The Rs 500-1500 cost of a culture is small next to the cost — and the resistance fallout — of a failed course.

The bigger stewardship issue is how Indian practice evolves. Self-medication, especially with fluoroquinolones, and over-the-counter antibiotic sales without prescription remain common despite regulations. As an individual you can help by not taking antibiotics without a proper diagnosis, finishing any prescribed course, never sharing antibiotics, and not using them for viral or non-bacterial illnesses.

Hospital and ICU rates of ESBL and carbapenem-resistant organisms run higher than community rates because of intense antibiotic pressure in those settings. This matters for any woman admitted to hospital, since healthcare-associated UTIs may involve more resistant bugs. India's National Action Plan on Antimicrobial Resistance is working on this, but progress is gradual.

Pregnancy changes everything about how cystitis is handled. The hormonal and anatomical shifts of pregnancy — smooth muscle relaxation, ureteral dilation, larger bladder capacity, and urinary stasis — raise UTI risk, and a bladder infection is more likely to climb to the kidneys. UTI in pregnancy is linked to preterm labour, low birth weight, and other adverse outcomes. For this reason, asymptomatic bacteriuria, which is usually left alone in non-pregnant adults, IS treated in pregnancy. Our guide to urinary tract changes in pregnancy covers what is normal versus a warning sign.

Screening for asymptomatic bacteriuria is standard antenatal care. ACOG and other obstetric bodies recommend a urine culture at the first prenatal visit and again in the third trimester, and Indian obstetric practice broadly follows this. Treating it cuts the risk of later pyelonephritis from around 20-30% to under 5%. A routine pregnancy urine culture in Indian private settings costs about Rs 500-1500 and is usually part of standard antenatal packages.

Symptomatic cystitis in pregnancy is treated promptly with pregnancy-safe antibiotics: nitrofurantoin 100 mg twice daily for 5-7 days (avoided in the last few weeks because of a risk of newborn haemolytic anaemia, especially in G6PD-deficient infants), cephalexin 500 mg four times daily for 5-7 days, amoxicillin-clavulanate 625 mg three times daily for 5-7 days, or fosfomycin 3 g single dose. Trimethoprim is avoided in the first trimester (folate antagonism), sulphonamides in the third trimester (kernicterus risk), and fluoroquinolones throughout.

Pyelonephritis in pregnancy is serious and usually needs hospital admission for intravenous antibiotics and fluids, monitoring for systemic and obstetric complications, and follow-up cultures. Hospitalisation in Indian private hospitals typically runs Rs 30,000-1,50,000 depending on duration, drugs, and complications.

Recurrent UTI in pregnancy may warrant preventive antibiotics for the rest of the pregnancy — cephalexin 250 mg or nitrofurantoin 50 mg at bedtime are common regimens, individualised by frequency, severity, and gestation. Post-sex (post-coital) prophylaxis is another option for women whose UTIs follow intercourse.

After delivery, UTI risk stays elevated for several weeks, particularly for women who had a UTI in pregnancy or a urinary catheter during birth. Evaluate symptoms promptly. Breastfeeding compatibility matters: nitrofurantoin and cephalexin are generally considered compatible; co-trimoxazole has cautions; tetracyclines and fluoroquinolones are usually avoided. When in doubt, your obstetrician or paediatrician (or the LactMed database) can confirm a specific drug. If you also developed gestational diabetes, tell your doctor, as it can raise infection risk.

Cystitis in postmenopausal women has distinctive features. UTI rates rise sharply after menopause, mainly because falling estrogen thins the vaginal tissue, depletes the protective lactobacilli, raises vaginal pH, and lets uropathogens colonise more easily. Symptoms may be less dramatic or atypical — vague pelvic discomfort, frequency without classic burning, or, in older women, changes in mental status.

Diagnosis follows the same principles: urinalysis and culture in symptomatic women. But atypical presentations can delay it, especially in the elderly, where confusion, lethargy, or functional decline should prompt a UTI check among other causes. Importantly, bacteria and white cells are common in elderly women's urine even without a true UTI, so symptoms — not urine findings alone — must guide treatment, otherwise asymptomatic bacteriuria gets treated needlessly and fuels resistance.

Treatment options mirror those in younger women — nitrofurantoin, co-trimoxazole (when sensitive), or fosfomycin — though the course is sometimes extended to 5-7 days given a slightly higher complication risk and slower clearance. Kidney function, drug interactions, and polypharmacy all influence the choice; renal function should be checked before nitrofurantoin.

For postmenopausal women with recurrent UTI, topical vaginal estrogen is one of the most effective preventive treatments: it restores vaginal estrogen, lactobacilli, and an acidic pH, substantially cutting recurrences. Indian formulations include conjugated estrogen vaginal cream (around Rs 1500-3500 per tube) and estradiol preparations, typically used daily for two weeks then twice weekly. NAMS, ACOG, and the Indian Menopause Society support this; systemic absorption is minimal and the safety profile is good for most women. Our guide to atrophic vaginitis and genitourinary syndrome of menopause goes deeper, and you can read more about the perimenopausal transition and intimacy after menopause.

Other prevention strategies include adequate hydration (often poor because thirst perception drops with age), regular voiding, evaluating for diabetes, and considering D-mannose or cranberry adjuncts. Prophylactic antibiotics are reserved for selected cases, since vaginal estrogen is often more effective and avoids resistance.

Recurrent UTI in older women also warrants looking for underlying causes. Pelvic organ prolapse, incontinence with incomplete emptying, bladder diverticula, and bladder stones all become more common with age. A pelvic exam, a post-void residual measurement, and sometimes imaging or urology referral may be appropriate, and treating the underlying problem — for example with pelvic floor exercises or prolapse repair — can sharply reduce UTI frequency.

Antibiotics usually bring noticeable relief within 24-48 hours, with full resolution over 3-5 days. During those first days, non-antibiotic measures can make a real difference to comfort — antibiotics plus supportive care beat antibiotics alone for many women.

Hydration is the single most useful supportive measure. Drinking enough water helps flush bacteria out, dilutes urine to ease the burning, and supports the kidneys. Aim for about 2-3 litres of fluid a day during active infection (more with fever), spread across the day rather than all at once. Water is best; other unsweetened fluids count. Go easy on alcohol and excess caffeine while you are infected.

Pain relief helps a lot. Paracetamol 500-1000 mg every 6-8 hours (maximum 3-4 g a day) is generally safe for the pelvic ache of cystitis. Ibuprofen 200-400 mg every 6-8 hours can be added if not contraindicated (avoid with active gastritis or ulcers, kidney disease, NSAID-triggered asthma, blood thinners, late pregnancy, or severe heart failure). Combining paracetamol with an NSAID often works better than either alone.

Heat on the lower belly — a hot water bag, heating pad, or warm compress — eases cramping and pelvic discomfort. A warm sitz bath can soothe and gently clean the external area; avoid water hot enough to scald. A heating pad on the lower back can help if there is back discomfort.

Urinary alkalinisers (Citralka, Cital, Alkasol and similar) are sold everywhere in India and often recommended for UTI relief, on the idea that more alkaline urine stings less. The evidence for real benefit is weak; they do not treat the infection and can interact with some antibiotics — notably nitrofurantoin, which works better in acidic urine. Use them short-term for symptom relief only if your doctor agrees, never as a substitute for proper treatment. A bottle costs around Rs 100-300.

Phenazopyridine (Pyridium) is a urinary analgesic available in India that specifically dulls the burning, frequency, and urgency by acting on the bladder lining. It does not treat infection and is used short-term (1-2 days) alongside antibiotics; the usual dose is 100-200 mg three times daily after meals. It turns urine orange-red (warn yourself, and protect clothing) and should be avoided in significant kidney impairment, G6PD deficiency, and with prolonged use. A short course costs around Rs 50-200.

What not to do: do not stop antibiotics early just because you feel better — feeling better does not mean the bacteria are gone, and stopping early raises the risk of recurrence and resistance. Finish the course. Do not share antibiotics, do not use leftovers from a previous prescription, and do not rely on home remedies, alkalinisers, or cranberry juice to cure a confirmed bacterial infection — they are supportive measures, not a cure.

Most acute cystitis responds to first-line antibiotics within 48-72 hours. When symptoms drag on past that, several possibilities arise: the bacteria are resistant to the drug chosen, the dose or duration was inadequate, the course was not completed, the diagnosis was wrong (symptoms from something else), or the infection is complicated. Lingering symptoms after a course do not always mean the antibiotic failed — our guide on UTI symptoms that linger after antibiotics explains why.

The first step when symptoms persist or recur is a urine culture, ideally before starting a different antibiotic. The culture identifies the organism and its sensitivities so treatment can be targeted. In India, given high ESBL rates, culture-guided treatment is often more effective than another empiric guess. A culture with sensitivities at Indian chain labs is typically Rs 500-1500.

Common reasons for failure here include choosing a drug the organism resists (often co-trimoxazole given regional resistance, fluoroquinolones given rising resistance, or some cephalosporins given ESBL), too short a course for the agent used, incomplete adherence, and complicating factors such as diabetes, stones, anatomical issues, or pelvic floor dysfunction.

When symptoms persist, the workup widens. Alongside a repeat culture with sensitivities, consider: a pelvic exam to look for vaginal causes (yeast, BV, atrophy); testing for sexually transmitted infections if relevant, since chlamydia and gonorrhoea can cause urethritis that mimics a UTI and can also lead to pelvic inflammatory disease; evaluation for non-infectious causes (interstitial cystitis, bladder irritants, tumours in older women); ultrasound for stones or anatomical problems; and a post-void residual measurement.

If a culture confirms a resistant organism, treatment is adjusted to the sensitivity pattern. ESBL E. coli cystitis may respond to nitrofurantoin (if susceptible and confined to the bladder), fosfomycin (single 3 g dose, sometimes repeated every 2-3 days), or oral pivmecillinam where available. More serious infections, such as pyelonephritis with ESBL organisms, may need intravenous carbapenems and hospital admission.

If symptoms persist even though a culture shows the bacteria are cleared, the problem may not be infection at all. Interstitial cystitis (painful bladder syndrome) causes UTI-like symptoms without infection and is managed with dietary changes, bladder training, medications, and sometimes bladder instillations — a urologist or urogynaecologist referral is appropriate.

Other persistent symptoms may reflect overactive bladder, post-infectious bladder irritability, pelvic floor dysfunction, or chronic pelvic pain. These need different evaluation and management. The key principle: ongoing UTI-like symptoms WITHOUT a positive culture deserve a broader workup, not repeated empiric antibiotic courses.

Most acute cystitis is uncomplicated and treatable at home, but certain features call for urgent or emergency review. The threshold should be lower in vulnerable groups: pregnant women, women with diabetes, the elderly, the immunocompromised, and those with significant other illnesses.

Seek prompt care for any of these red flags: fever above 38°C (100.4°F); chills or rigors; flank or back pain, especially on one side over the kidney; nausea and vomiting that stop you keeping fluids down; severe pelvic or abdominal pain; large amounts of visible blood in urine; inability to pass urine or passing only a trickle; new confusion (especially in older women); and signs of serious illness such as light-headedness, a racing heart, low blood pressure, or feeling very unwell.

These can indicate pyelonephritis (kidney infection) or urosepsis (infection in the bloodstream) — both more serious, often needing intravenous antibiotics and sometimes hospital admission. Pyelonephritis in an otherwise healthy non-pregnant woman can sometimes be managed at home with oral antibiotics if symptoms are mild; pregnant women with pyelonephritis usually need admission. Septic shock is a medical emergency.

In pregnancy, the bar is much lower. Any UTI symptom in pregnancy deserves same-day or next-day review, and fever, vomiting, or back pain needs urgent assessment, because untreated pyelonephritis carries real risk of preterm labour, sepsis, and harm to the baby.

In women with diabetes, a UTI can progress quickly to pyelonephritis, emphysematous cystitis (a serious form with gas in the bladder wall), or a kidney abscess. Evaluate symptoms promptly and tighten glucose control alongside antibiotics; admission may be needed when diabetes is poorly controlled. (See our guide to managing diabetes in Indian women.)

In elderly women, presentations are often atypical — confusion, falls, lethargy, poor appetite, or general decline may be the only clues. Family members should stay alert to such changes, since UTI in this group carries higher rates of pyelonephritis, sepsis, and acute kidney injury.

Practical guidance: get a same-day review for new UTI symptoms, especially if it is your first time or severe; seek same-day or emergency care for any red flag; follow up if symptoms persist beyond 48-72 hours of antibiotics; and arrange a proper workup for recurrent UTI (more than two in six months or three in a year). In India, a primary care or gynaecology consult (Rs 500-2500 private, less in government settings) costs far less than an inadequately treated UTI or a missed kidney infection. If you ever feel dismissed, do not hesitate to ask for a urine test and a clear explanation of your treatment plan.

• IDSA & ESCMID — International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women
• NHS — Cystitis: Symptoms, Causes and Treatment
• American Urological Association — Recurrent Uncomplicated Urinary Tract Infections in Women Guideline
• ACOG — Urinary Tract Infections in Pregnant Individuals (Clinical Guidance)
• Indian Council of Medical Research (ICMR) — Treatment Guidelines for Antimicrobial Use in Common Syndromes
• National Centre for Disease Control (India) — National Action Plan on Antimicrobial Resistance